新型预融合mRNA与蛋白疫苗联合增强对呼吸道合胞病毒的中和抗体与保护作用
研究开发了含原型DS-Cav1预融合稳定化及额外融合结构域突变的新型预融合mRNA疫苗,在小鼠中可诱导中和抗体和偏好Th1型效应T细胞反应。预融合mRNA-LNP与预融合蛋白联合诱发的针对RSV A和B株的中和抗体滴度显著高于单独使用任一疫苗,并通过清除肺部病毒载量、预防肺组织病理和炎症提供保护。
要点
- 新型预融合mRNA-LNP疫苗在小鼠中有效诱导中和抗体和偏好Th1型效应T细胞反应。
- 预融合mRNA-LNP与预融合蛋白联合诱发的RSV A和B株中和抗体滴度显著高于单独使用任一疫苗。
- 联合疫苗通过清除肺部病毒载量、预防肺组织病理和炎症提供保护,并调节平衡的效应CD8 T细胞反应。
核心结论
- 本研究支持将预融合mRNA与预融合蛋白疫苗联合可提供比单独使用mRNA或蛋白疫苗更有效的体液免疫和平衡的细胞免疫。
研究设计与样本
- 研究开发了含原型DS-Cav1预融合稳定化及额外融合结构域突变的新型预融合mRNA疫苗,封装于脂质纳米颗粒(LNP),并在小鼠中评估免疫应答和保护效果。
主要发现
- 新型预融合mRNA-LNP疫苗在小鼠中有效诱导中和抗体和偏好Th1型效应T细胞反应。
- 预融合mRNA-LNP与预融合蛋白联合诱发的针对RSV A和B株的中和抗体滴度显著高于单独使用预融合mRNA或蛋白疫苗。
- 与原型预融合蛋白相比,预融合mRNA及其与预融合蛋白联合通过清除肺部病毒载量、预防肺组织病理和炎症提供保护。
- 联合预融合mRNA和预融合蛋白疫苗接种在攻毒后调节平衡的效应CD8 T细胞反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus (RSV) causes high hospitalization and mortality in children and the elderly. RSV prefusion conformation-stabilized fusion (F) protein vaccines have been licensed for elderly and maternal vaccination. Nonetheless, a demand exists for an effective RSV vaccine in elderly and young children, avoiding vaccine-enhanced disease. We developed a new prefusion mRNA containing a prototype (DS-Cav1 pre-F) stabilizing and additional fusion domain mutations. The new pre-F mRNA vaccine, encapsulated in lipid nanoparticles (LNP), effectively induced neutralizing antibodies and a preferential Th1-type effector T cell response in mice. Remarkably, a combination of pre-F mRNA-LNP and pre-F protein elicited significantly higher titers of neutralizing antibodies against RSV A and B strains than either pre-F mRNA or protein vaccine alone. Pre-F mRNA and its combination with pre-F protein provided protection by clearing lung viral loads, preventing lung histopathology and inflammation, compared to the prototype pre-F protein. Combination pre-F mRNA and pre-F protein vaccination modulated balanced effector CD8 T cell responses after challenge. This study supports the idea that combining pre-F mRNA and pre-F protein vaccines would provide more effective humoral and balanced cellular immunity than either mRNA or protein vaccine alone.
引用
- Pal SS, Kim KH, Bhatnagar N, et al. A combination of new prefusion mRNA and protein vaccines enhances neutralizing antibodies and protection against respiratory syncytial virus. Vaccine. 2025. PMID: 41455187. doi:10.1016/j.vaccine.2025.128154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。